Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push
Eli Lilly and Co. has agreed to a partnership with artificial intelligence-driven drug discovery company Insilico that could be worth up to $2.75 billion, amid an expanding category of collaboration fueled by...To view the full article, register now.
Already a subscriber? Click here to view full article